Interest in diabetes technology is exploding. Over the past few months we’ve seen the approval of Dexcom’s (NASDAQ:DXCM) continuous glucose monitor and Medtronic’s (NYSE:MDT) sensor augmented insulin pump. LifeScan, a division of Johnson and Johnson (NYSE:JNJ), introduced the Ultra 2 blood glucose meter, while their rival Roche introduced the Accu-Chek Compact Plus.
Concurrently the research community is zeroing in on a new area, Glycemic Variability (GV). Armed with CGM technology, physicians and patients now have a clearer picture of the variances in glucose levels. There is a growing body of evidence showing that patients with a greater degree of GV are more likely to experience a cardiovascular event. Look for GV to be a major topic at the upcoming American Diabetes Association Scientific Sessions.